1 Company Diving off the Patent Cliff

The recent performance of some big pharma stocks might have some investors thinking that the patent cliff is nothing to worry about. It's easy to understand how that sort of attitude could exist. Take the performance of a stock like Eli Lilly (NYS: LLY) as an example. Shares have risen some 35% in the past year despite the fact that two huge drugs come off patent next year.

In the following video, health care bureau chief Brenton Flynn runs through the situation, and outlines some recent news that could help the company offset these losses by taking share in the lucrative diabetes market.Â

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article 1 Company Diving off the Patent Cliff originally appeared on Fool.com.

Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.